Zosano Pharma Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-11-13: Form 8-K; Period of report 2020-11-12; Description 2.02 Results of Operations and Financial Condition; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 2.02.
- 2020-10-21: Form 8-K; Period of report 2020-10-20; Description 8.01 Other Events; Details 8.01.
- 2020-09-30: Form 8-K; Period of report 2020-09-29; Description 8.01 Other Events; Details 8.01.
- 2020-09-03: Form 8-K; Period of report 2020-08-31; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-11-13 | 8-K | 2020-11-12 | 2.02 Results of Operations and Financial Condition; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 2.02 On November 13, 2020, Zosano Pharma Corporation (the "Company") issued a press release titled “Zosano Pharma Reports Third Quarter 2020 Financial Results.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. 3.01 On November 12, 2020, the Company received written notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(a)(2). | zsan-20201112.htm |
| 2020-10-21 | 8-K | 2020-10-20 | 8.01 Other Events | 8.01 On October 20, 2020, Zosano Pharma Corporation (the “Company”) received a complete response letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (“NDA”). | d11044d8k.htm |
| 2020-09-30 | 8-K | 2020-09-29 | 8.01 Other Events | 8.01 On September 29, 2020, Zosano Pharma Corporation (the “Company”) received a discipline review letter (“DRL”) from the U.S. Food and Drug Administration (“FDA”) in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (“NDA”). | d56118d8k.htm |
| 2020-09-03 | 8-K | 2020-08-31 | 8.01 Other Events | 8.01 On August 31, 2020, Zosano Pharma Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BTIG, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell 15,937,130 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), to the Underwriter (the “Offering”). | d78642d8k.htm |
| 2020-08-31 | 8-K | 2020-08-31 | 7.01 Regulation FD Disclosure | 7.01 On August 31, 2020, Zosano Pharma Corporation (the “Company”) disclosed certain preliminary financial information. | d946229d8k.htm |
| 2020-08-17 | 8-K | 2020-08-14 | 8.01 Other Events | 8.01 As previously reported, on March 26, 2020, Zosano Pharma Corporation (the “Company”) received a notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. | zsan-20200814.htm |
| 2020-08-11 | 8-K | 2020-08-06 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d921916d8k.htm |
| 2020-08-06 | 8-K | 2020-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2020, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | zsan-20200806.htm |
| 2020-08-06 | 8-K | 2020-07-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d58409d8k.htm |
| 2020-06-29 | 8-K | 2020-06-29 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 25, 2020, Zosano Pharma Corporation (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). | a2020annualshareholdermeet.htm |
| 2020-06-15 | 8-K | 2020-06-15 | 8.01 Other Events | 8.01 On June 13, 2020, Zosano Pharma Corporation (the “Company”) announced that new post-hoc efficacy analyses of QtryptaTM, the Company’s lead investigational product candidate for the acute treatment of migraine, would be presented as a virtual oral presentation on the 2020 American Headache Society’s Virtual Annual Scientific Meeting Platform. | pressreleasenewpost-hocana.htm |
| 2020-06-08 | 8-K | 2020-06-08 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d936083d8k.htm |
| 2020-05-28 | 8-K | 2020-05-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d75045d8k.htm |
| 2020-05-14 | 8-K | 2020-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2020, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | q1earnings.htm |
| 2020-05-01 | 8-K | 2020-04-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 8, 2020, Zosano Pharma Corporation (the “Company”) filed a Current Report on Form 8-K (as amended by Amendment No. 1 on Form 8-K/A filed on March 4, 2020) reporting the appointment of Christine Matthews as interim chief financial officer. | d833413d8k.htm |
| 2020-04-23 | 8-K | 2020-04-23 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information contained in Item 1.01 is hereby incorporated by reference into this Item 2.03. | a8-k.htm |
| 2020-04-21 | 8-K/A | 2020-03-26 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On March 27, 2020, Zosano Pharma Corporation (the “Company”) filed a Current Report on Form 8-K reporting that the Company had received notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market and that it has a period of 180 calendar days, or until September 22, 2020, to regain compliance with the minimum bid price requirement. | d842575d8ka.htm |
| 2020-03-27 | 8-K | 2020-03-27 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On March 26, 2020, Zosano Pharma Corporation (the “Company”) received written notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(a)(2). | nasdaq8k.htm |
| 2020-03-13 | 8-K | 2020-03-13 | 2.02 Results of Operations and Financial Condition | 2.02 On March 13, 2020, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports Fourth Quarter and Fiscal Year 2019 Financial Results.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | q42019earning8k.htm |
| 2020-03-06 | 8-K | 2020-03-04 | 1.01 Entry into a Material Definitive Agreement | 1.01 On March 4, 2020, Zosano Pharma Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale in a registered direct offering of (i) 11,903,506 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and (ii) warrants to purchase up to a total of 11,903,506 shares of Common Stock (the “Warrants”) at an offering price of $0.9275 per share and accompanying Warrant. | d895307d8k.htm |
| 2020-03-04 | 8-K | 2020-03-04 | 8.01 Other Events | 8.01 On March 4, 2020, Zosano Pharma Corporation (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") accepted the Company’s New Drug Application (the "NDA") for Qtrypta™ for filing and substantive review. | nda8k.htm |
| 2020-03-04 | 8-K | 2020-03-04 | 1.02 Termination of a Material Definitive Agreement | 1.02 On August 19, 2019, Zosano Pharma Corporation (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”) to sell shares of the Company’s common stock with aggregate gross sales proceeds of up to $15,000,000, from time to time, through an at the market offering (the “ATM”) with BTIG as a sales agent. | d859506d8k.htm |
| 2020-03-04 | 8-K/A | 2020-01-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 8, 2020, Zosano Pharma Corporation (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) reporting the appointment of Christine Matthews as interim chief financial officer, effective February 1, 2020. | d900761d8ka.htm |
| 2020-02-13 | 8-K | 2020-02-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 On February 12, 2020, Zosano Pharma Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”) related to the public offering by the Company of (i) 10,146,154 Class A Units, each consisting of one share of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) and one Series C Common Stock Purchase Warrant (“Series C Warrant”) to purchase one share of Common Stock, at a public offering price of $0.65 per Class A Unit, and (ii) 2,161,539 Class B Units, each consisting of one Series D Pre-Funded Common Stock Purchase Warrant (“Series D Warrant”) to purchase one share of Common Stock and one Series C Warrant to purchase one share of Common Stock, at a public offering price of $0.6499 per Class B Unit. | d888112d8k.htm |
| 2020-02-11 | 8-K | 2020-02-11 | 2.02 Results of Operations and Financial Condition | 2.02 On February 11, 2020, Zosano Pharma Corporation (the “Company”) intends to disclose certain preliminary financial information. | d162105d8k.htm |
| 2020-02-11 | 8-K | 2020-02-10 | 8.01 Other Events | 8.01 On February 10, 2020, Zosano Pharma Corporation posted an updated corporate presentation to its website. | d115177d8k.htm |
| 2020-01-08 | 8-K | 2020-01-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On January 3, 2020, Gregory Kitchener, the chief financial officer of Zosano Pharma Corporation (the “Company”), notified the Company of his intent to resign effective February 1, 2020. | d860779d8k.htm |